PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|April 20, 2016
Walker Barrier Systems Products to be Rebranded as Extract Technology
Author(s)Pharmaceutical Technology Editors
Extract Technology’s portfolio will now include aseptic solutions, containment solutions, restricted access barriers, and mobile cleanrooms for the pharmaceutical, healthcare, biotech and chemical markets.
Advertisement
Wabash National Corporation will begin marketing all Walker Barrier Systems products as Extract Technology, the company said in an April 19, 2016 press announcement. The Extract Technology portfolio will now include aseptic solutions, containment solutions, restricted access barriers, and mobile clean rooms for the pharmaceutical, healthcare, biotech, and chemical markets. Wabash National’s operations in Huddersfield, England, and New Lisbon, Wisconsin, will continue to manufacture all aseptic and containment systems.
Alan Wainwright has been named the global managing director, Extract Technology Limited. He will oversee manufacturing operations in Huddersfield and New Lisbon and will be responsible for overseeing product development. Extract Technology, a containment and aseptic manufacturer, plans to continue its international market growth by adding mobile cleanrooms to its portfolio, which Walker Barrier Systems began manufacturing in 2013.
Source: Wabash National Corporation
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement